Search
Pyrazoloacridine
go.drugbank.com/drugs/DB12549InvestigationalPyrazoloacridine has been used in trials studying the treatment of Lung Cancer, Liver Cancer, Breast Cancer, Melanoma (Skin), and Metastatic Cancer, among others.
Categories: Compounds used in a research, industrial, or household settingAbexinostat
go.drugbank.com/drugs/DB12565InvestigationalIt is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.
Dacetuzumab
go.drugbank.com/drugs/DB12589InvestigationalIt is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Mosedipimod
go.drugbank.com/drugs/DB12592InvestigationalMosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
Etripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigationalEtripamil is a nondihydropyridine, L-type calcium channel blocker.[A275238, L54728] It is a fast-acting drug with a short duration of action.
Davunetide
go.drugbank.com/drugs/DB12613InvestigationalDavunetide is derived from a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein.
ST-101
go.drugbank.com/drugs/DB12621InvestigationalST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.[A260411]
Bardoxolone
go.drugbank.com/drugs/DB12651InvestigationalIt is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells that are under high levels of intrinsic
Ibalizumab
go.drugbank.com/drugs/DB12698ApprovedInvestigationalIn October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448] … Ibalizumab (also known as _ibalizumab-uiyk_ and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into
CYNK-101
go.drugbank.com/drugs/DB18637InvestigationalCYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Synonyms: allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP)